A5064934995- HIV Research and Treatment
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- Herpesvirus Infections and Treatments
- HIV/AIDS drug development and treatment
- Transgenic Plants and Applications
- HIV/AIDS Research and Interventions
- Cytomegalovirus and herpesvirus research
- Glycosylation and Glycoproteins Research
- SARS-CoV-2 and COVID-19 Research
- T-cell and B-cell Immunology
- Cancer-related gene regulation
- Monoclonal and Polyclonal Antibodies Research
- Reproductive tract infections research
BioScience Laboratories (United States)
2005-2018
Advanced Bioscience Laboratories (United States)
2006-2018
Profectus Biosciences (United States)
2006
ABSTRACT The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV acquisition in the RV144 vaccine trial. This outcome was unexpected, given limited ability components to induce CD8 + T-cell responses or broadly neutralizing antibodies. We vaccinated macaques an immunization regimen intended mimic trial and exposed them intrarectally a dose simian SIV mac251 that transmits few...
As sexual transmission of human immunodeficiency virus-1 (HIV-1) occurs via the mucosa, an ideal HIV-1 vaccine should induce both mucosal and systemic immunity. We therefore sought to evaluate induction responses using a DNA env prime–gp120 protein boost approach in which sequential nasal parenteral administration was performed with two novel carbohydrate-based adjuvants. These adjuvants, Advax-M Advax-P, were specifically designed for immune enhancement, respectively. Murine intranasal...
Transmission of human immunodeficiency virus type 1 (HIV-1) occurs primarily via the mucosal route, suggesting that HIV-1 vaccines may need to elicit immune responses. Here, we investigated immunogenicity and relative efficacy systemic immunization with two ALVAC-HIV-1 recombinant expressing Gag, Pol, gp120 (vCP250) or gp160 (vCP1420) in a prime-boost protocol their homologous vaccine native Env proteins. The was measured against high-dose exposure pathogenic neutralization-resistant variant...
Immunization of macaques with multivalent DNA encoding gp120 genes from HIV-1 subtypes A, B, C and E a gag gene followed by boosting homologous proteins elicited strong anti-gp120 antibodies capable neutralizing to lesser degree heterologous isolates. Both Env- Gag-specific cell mediated immune (CMI) responses were detected in the immunized animals. Following rectal challenge an SHIV isolate HIV-1(Ba-L)env, plasma viremia infected animals was significantly lower than that observed naïve...
A potential strategy to combat the worldwide AIDS epidemic is develop a vaginal microbicide that prevents sexual transmission of HIV-1. One approach for preventing HIV block viral coreceptor CCR5 with naturally occurring chemokine ligands. In this study, we used cynomolgus macaque model evaluate whether variant ligand RANTES (-2 RANTES), tested alone or in nonphospholipid liposome carrier (Novasomes 7474), blocks challenge CCR5-tropic simian/human immunodeficiency virus (SHIV(162P3)). When...
HIV-1 infection can be controlled by anti-retroviral drug therapy, but this is a lifetime treatment and the virus remains latent rapidly rebounds if therapy stopped. HIV-1-infected individuals under regimen have increased rates of cancers, cardiovascular diseases, autoimmunity due to compromised immunity. A therapeutic vaccine boosting cellular immunity against therefore desirable and, possibly combined with other immune modulating agents, could obviate need for long-term therapies. An...
The late assembly domain of many viruses is critical for budding. Within these domains, encoded in viral structural proteins, are the conserved motifs PTAP, PPxY and YPxL. These sequences key determinants association proteins with intracellular molecules such as Tsg101, Nedd4 AIP1/ALIX. While roles Tsg101 AIP1/ALIX HIV-1 budding have been well established, less known about role Nedd4. Recent studies, however, identified a function Nedd4-like protein release. In this study, we investigated...
Background The canarypox vector ALVAC-HIV, together with the HIV gp120 envelope, has protected 31.2% of Thai heterosexual individuals from acquisition in RV144 vaccine trial. This outcome was unexpected, given limited ability ALVAC-HIV component to induce CD8+T-cell responses, and HIVgp120 envelope elicit broad neutralizing antibodies. Methods We vaccinated macaques an immunization regimen that mimics trial exposed them a mucosal dose SIVmac251 transmits few virus variants, similar...
Background Since HIV transmits primarily via mucosal route during sexual transmission; an ideal HIV-1 vaccine should induce both systemic and humoral cellular responses. Although envelope formulated with QS21 or Alum elicits strong antibody responses, T-cell responses are generally weak. Herein we examined the immune elicited following a DNA prime/protein boost inulin-derived (Advax) adjuvants. Such adjuvants have been shown to be less reactogenic can in compartments.
Epitopes located in and around the coreceptor binding site of gp120 represent some most conserved functionally important sequences HIV envelope. Many these epitopes can be exposed prior to and/or after attachment a manner determined by envelope sequence infection system. Furthermore, are immunogenic humans elicit cognate antibodies exhibiting range structures fine specificities. These features suggest that CD4i should carefully evaluated for potential utility vaccine development. Experiments...